Skip to content

Study · Non-randomized trial · n = 21 · 2006

5 results

Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty.

Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, Wintergerst K, Chi C, Klein KO, Neely EK

The Journal of clinical endocrinology and metabolism31 Jan 2006Cited by 58 (Europe PMC)

PMID16449344 (opens in a new tab)DOI10.1210/jc.2005-1500 (opens in a new tab)PepBankPUB-16449344
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In CPP patients, stimulated LH was higher with 3.75 mg than 7.5 mg monthly leuprolide.

    In plain wordsIn CPP patients, stimulated LH was higher with 3.75 mg than 7.5 mg monthly leuprolide.

    Peptide
    Leuprolide
    Outcome
    IncreaseStimulated LH, lower monthly dose
    Study

    n = 21

    Comparator
    Leuprolide 7.5 mg every 4 weeks
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg every 4 weeksAs given in this study (human).

    Measurements

    Mean LH
    1.73
    3.75 mg
    Mean LH
    1.3
    7.5 mg
    P
    0.019
    comparison

    Source sentences

    Summary
    DL-stimulated LH levels (mean +/- sd) were 1.30 +/- 0.74, 1.73 +/- 0.99, and 2.13 +/- 1.41 on 7.5 mg, 3.75 mg, and 11.25 mg-3 month, respectively (7.5 vs. 3.75 mg, P = 0.019; 7.5 mg vs. 11.25 mg-3 month, P = 0.004, Wilcoxon ranked sign test).
    2 context sentences
    Summary · context
    In an open 12-month protocol, we tested the efficacy of three DL doses (7.5 mg- and 3.75 mg-1 month and 11.25 mg-3 month) given sequentially to subjects treated for CPP.
    Summary · context
    Thirty subjects were enrolled (20 naive; 24 girls, 6 boys), and 21 were evaluated on all three DL doses.
  2. 02HumanNon-randomized trialEfficacy outcome

    In CPP patients, stimulated LH was higher with three-month 11.25 mg than monthly 7.5 mg leuprolide.

    In plain wordsIn CPP patients, stimulated LH was higher with three-month 11.25 mg than monthly 7.5 mg leuprolide.

    Peptide
    Leuprolide
    Outcome
    IncreaseStimulated LH, three-month dose
    Study

    n = 21

    Comparator
    Leuprolide 7.5 mg every 4 weeks
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    11.25 mg every 3 monthsAs given in this study (human).

    Measurements

    Mean LH
    2.13
    11.25 mg
    Mean LH
    1.3
    7.5 mg
    P
    0.004
    comparison

    Source sentences

    Summary
    DL-stimulated LH levels (mean +/- sd) were 1.30 +/- 0.74, 1.73 +/- 0.99, and 2.13 +/- 1.41 on 7.5 mg, 3.75 mg, and 11.25 mg-3 month, respectively (7.5 vs. 3.75 mg, P = 0.019; 7.5 mg vs. 11.25 mg-3 month, P = 0.004, Wilcoxon ranked sign test).
    2 context sentences
    Summary · context
    In an open 12-month protocol, we tested the efficacy of three DL doses (7.5 mg- and 3.75 mg-1 month and 11.25 mg-3 month) given sequentially to subjects treated for CPP.
    Summary · context
    Thirty subjects were enrolled (20 naive; 24 girls, 6 boys), and 21 were evaluated on all three DL doses.
  3. 03HumanNon-randomized trialEfficacy outcome

    In CPP patients, FSH was higher with 3.75 mg than 7.5 mg monthly leuprolide.

    In plain wordsIn CPP patients, FSH was higher with 3.75 mg than 7.5 mg monthly leuprolide.

    Peptide
    Leuprolide
    Outcome
    IncreaseStimulated FSH, lower monthly dose
    Study

    n = 21

    Comparator
    Leuprolide 7.5 mg every 4 weeks
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg every 4 weeksAs given in this study (human).

    Measurements

    Mean FSH
    3.91
    3.75 mg
    Mean FSH
    2.86
    7.5 mg
    P
    0.017
    comparison

    Source sentences

    Summary
    Mean FSH levels were 2.86 +/- 1.91, 3.91 +/- 1.98, and 3.96 +/- 1.34, respectively (7.5 vs. 3.75 mg, P = 0.017; 7.5 mg vs. 11.25 mg-3 month, P = 0.020).
    2 context sentences
    Summary · context
    In an open 12-month protocol, we tested the efficacy of three DL doses (7.5 mg- and 3.75 mg-1 month and 11.25 mg-3 month) given sequentially to subjects treated for CPP.
    Summary · context
    Thirty subjects were enrolled (20 naive; 24 girls, 6 boys), and 21 were evaluated on all three DL doses.
  4. 04HumanNon-randomized trialEfficacy outcome

    In CPP patients, FSH was higher with three-month 11.25 mg than monthly 7.5 mg leuprolide.

    In plain wordsIn CPP patients, FSH was higher with three-month 11.25 mg than monthly 7.5 mg leuprolide.

    Peptide
    Leuprolide
    Outcome
    IncreaseStimulated FSH, three-month dose
    Study

    n = 21

    Comparator
    Leuprolide 7.5 mg every 4 weeks
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    11.25 mg every 3 monthsAs given in this study (human).

    Measurements

    Mean FSH
    3.96
    11.25 mg
    Mean FSH
    2.86
    7.5 mg
    P
    0.02
    comparison

    Source sentences

    Summary
    Mean FSH levels were 2.86 +/- 1.91, 3.91 +/- 1.98, and 3.96 +/- 1.34, respectively (7.5 vs. 3.75 mg, P = 0.017; 7.5 mg vs. 11.25 mg-3 month, P = 0.020).
    3 context sentences
    Summary · context
    DL-stimulated LH levels (mean +/- sd) were 1.30 +/- 0.74, 1.73 +/- 0.99, and 2.13 +/- 1.41 on 7.5 mg, 3.75 mg, and 11.25 mg-3 month, respectively (7.5 vs. 3.75 mg, P = 0.019; 7.5 mg vs. 11.25 mg-3 month, P = 0.004, Wilcoxon ranked sign test).
    Summary · context
    In an open 12-month protocol, we tested the efficacy of three DL doses (7.5 mg- and 3.75 mg-1 month and 11.25 mg-3 month) given sequentially to subjects treated for CPP.
    Summary · context
    Thirty subjects were enrolled (20 naive; 24 girls, 6 boys), and 21 were evaluated on all three DL doses.
  5. 05HumanNon-randomized trialEfficacy outcome

    In CPP patients, mean sex steroid levels did not differ across the tested leuprolide doses.

    In plain wordsIn CPP patients, mean sex steroid levels did not differ across the tested leuprolide doses.

    Peptide
    Leuprolide
    Outcome
    No significant changeMean sex steroid levels
    Study

    n = 21

    Comparator
    Other tested leuprolide depot doses
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No differences were detected in mean sex steroid levels.
    2 context sentences
    Summary · context
    In an open 12-month protocol, we tested the efficacy of three DL doses (7.5 mg- and 3.75 mg-1 month and 11.25 mg-3 month) given sequentially to subjects treated for CPP.
    Summary · context
    Thirty subjects were enrolled (20 naive; 24 girls, 6 boys), and 21 were evaluated on all three DL doses.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.